Organon Licenses Sebela’s MIUDELLA IUD to Expand Contraception Portfolio
Event summary
- Organon has completed a global licensing agreement for MIUDELLA®, Sebela’s hormone-free copper IUD, approved by the FDA in February 2025.
- MIUDELLA is the first hormone-free copper IUD introduced in the US in over 40 years and is 99% effective for up to three years.
- The product features SLIMSERT™ technology with a flexible frame and preloaded inserter, aiming for commercial availability in late 2026.
- MIUDELLA will be available only through the MIUDELLA REMS program due to risks associated with improper insertion.
The big picture
Organon’s acquisition of MIUDELLA strengthens its position in the long-acting reversible contraception market, addressing a growing demand for hormone-free options. The deal aligns with broader industry trends toward personalized women’s health solutions and regulatory scrutiny over device safety.
What we're watching
- Market Penetration
- How Organon will leverage its scale to drive MIUDELLA’s adoption in a competitive contraception market.
- Regulatory Compliance
- Whether the REMS program will effectively mitigate risks and ensure proper insertion training for healthcare providers.
- Execution Risk
- The pace at which Organon can commercialize MIUDELLA while managing potential adverse reactions and discontinuation rates.
Related topics